The parp inhibitor market consists of drugs that inhibit the activity of poly ADP ribose polymerase enzymes. Parp inhibitors are primarily used for the treatment of cancers like breast, ovarian, prostate and pancreatic cancer. They are effective in treating cancers with defects in homologous recombination repair genes like BRCA1 and BRCA2. Parp inhibitors prevent cancer cells from repairing damaged DNA which leads to cell death. The rising prevalence of various cancers worldwide has fueled the demand for effective targeted therapies like parp inhibitors. As per GLOBOCAN 2020 estimates, about 19.3 million new cancer cases and 10 million cancer deaths occurred globally in 2020. The strong pipeline of parp inhibitors and increasing approvals for new indications are expected to drive market growth during the forecast period. The global parp inhibitor market is estimated to be valued at US$ 7.85 Bn in 2025 and is expected to exhibit a CAGR of 9.0% over the forecast period of 2025 to 2032. Key Takeaways Key players operating in the parp inhibitor market are AstraZeneca, GlaxoSmithKline, Merck Co. & Inc, GlaxoSmithKline plc, AbbVie Inc, Clovis Oncology, Medivation. AstraZeneca's Lynparza and Merck's Lynparza occupy a bulk of the market share currently. The PARP inhibitors Market Demand provides numerous opportunities for companies. PARP inhibitors are being studied in combination with immunotherapy agents for treatment of various cancers. Several clinical trials are ongoing to expand the usage of parp inhibitors into new cancer indications. For instance, ongoing trials are exploring use of parp inhibitors for prostate, pancreatic and gastric cancers. Key players are actively pursuing strategies to grow their global footprint. Companies are focusing on regulatory approvals in new regions and territories. Manufacturers are also undertaking initiatives to enhance affordability and accessibility of parp inhibitors in underdeveloped and developing countries worldwide through various awareness and patient assistance programs. This will help drive the global adoption of parp inhibitors. Market Drivers - Rising disease burden of cancer due to increasing risk factors like obesity, sedentary lifestyle, pollution etc has increased the demand for effective targeted cancer therapies like parp inhibitors. Expanding patient pool creates a strong need for these drugs. Market Restrains - High costs of parp inhibitors hamper widespread adoption. At an average cost of over USD 10,000 per month, affordability remains a challenge especially in developing nations with budget constraints in the healthcare system. Stringent regulations surrounding approval of new cancer drugs also acts as a barrier.
Segment Analysis The PARP inhibitor market is segmented into olaparib, rucaparib, niraparib and others. Among them, olaparib segment holds the highest share in the global market owing to its FDA approval in 2014 for treating advanced ovarian cancer with BRCA gene mutations. Olaparib was the first approved PARP inhibitor drug and benefits from patent exclusivity. However, the niraparib segment is anticipated to grow at a faster rate during the forecast period. Niraparib has shown activity in women with ovarian cancer irrespective of BRCA mutations and has a wide range of approval for recurrent ovarian cancer treatment. Global Analysis Regionally, North America dominates the PARP inhibitor market due to regulatory support, high awareness about cancer diagnosis and available funding for research & development. Additionally, the US accounts for the largest share in North America due to the presence of major players and availability of advanced healthcare facilities. However, the Asia Pacific region is anticipated to witness the highest CAGR during the forecast period owing to increasing healthcare expenditure and rising cancer prevalence in developing countries such as India and China. Growing medical tourism also contributes to the rising demand for PARP inhibitors in the region.
Get this report in Japanese Language- PARP阻害剤市場
Get this report in Korean language- PARP 억제제 시장
About Author-
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.
(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)
